Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
CytomX Therapeutics, Inc. (NASDAQ: CTMX)
CTMX Stock Predictions and Ratings
WSX Rating:
SELL
WSX Forecast (1yr):
-4.50%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
318.80%
CTMX Stock Analysis
CTMX
PE Ratio:
CTMX
PEG Ratio:
Not Available
CTMX
Forward EPS Growth (12 month):
0.00%
CTMX
PS Ratio:
14.6
CTMX
PSG Ratio:
3.3
CTMX
Forward Revenue Growth (12 month):
4.40%
CTMX Articles
No data was found